Zobrazeno 1 - 10
of 538
pro vyhledávání: '"Baek-Yeol Ryoo"'
Autor:
Kyu-Pyo Kim, Kang Mo Kim, Baek-Yeol Ryoo, Won-Mook Choi, Won Chul Cha, Mira Kang, Dong Hyun Sinn, Myung Ji Goh, Do Young Kim, Min Ji Lee, Subin Lim, DongKyu Kim, Kyoungdae Baek, Joohyun Kim, Eui Jun Choi, Doik Lee, Jung-Ae Kim, Ki-Hun Kim
Publikováno v:
Liver Cancer, Pp 1-19 (2024)
Introduction: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with treatment outcomes closely tied to liver function. This study evaluates the prognostic utility of the albumin-bilirubin (ALBI) score compa
Externí odkaz:
https://doaj.org/article/1aa37e0aefcf496caf8b272eaff7fe77
Autor:
Joo Young Kim, Jisup Kim, Yong-il Kim, Dong-Hoon Yang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Somatostatin analogues have recently been used as therapeutic targets for metastatic or surgically unresectable gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), and associated somatostatin receptor (SSTR) expression has been well d
Externí odkaz:
https://doaj.org/article/e4e73fe04ec64937b6d26c6991a43ad7
Publikováno v:
EJNMMI Physics, Vol 11, Iss 1, Pp 1-18 (2024)
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE has shown efficacy in patients with metastatic neuroendocrine tumours (NETs). Personalised dosimetry is crucial to optimise treatment outcomes and minimise adve
Externí odkaz:
https://doaj.org/article/2d1485bc8836479b80df9671f776707e
Autor:
Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park
Publikováno v:
Gut and Liver, Vol 18, Iss 1, Pp 116-124 (2024)
Background/Aims: Sorafenib is the standard of care in the management of advanced hepatocellular carcinoma (HCC). The purpose of this study was to investigate the characteristics, treatment patterns and outcomes of sorafenib among HCC patients in Sout
Externí odkaz:
https://doaj.org/article/785dff6945e744c09e895390ae02284a
Autor:
Do-Youn Oh, Seung-Tae Kim, Sun Young Rha, Anthony El-Khoueiry, Hong Jae Chon, Jaspreet Grewal, Jeongjun Kim, Hyunji Ahn, Jinho Choi, Seung-Hee Ryu, Jiye Ahn, Bae Jung Choi, Hwankyu Kang, Yeong-In Yang, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Kiyean Nam, Baek-Yeol Ryoo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ec1c164f909d43019e62a0cb0a2eb0bb
Autor:
Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 7784-7794 (2023)
Abstract Background In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first‐line chemotherapy in advanced gastric cancer. Patients and Methods Patients with m
Externí odkaz:
https://doaj.org/article/282b0a8fa02d4899b6eff2f3eaf72e70
Autor:
Kyunghye Bang, Andrea Casadei‐Gardini, Changhoon Yoo, Massimo Iavarone, Min‐Hee Ryu, Sook Ryun Park, Hyung‐Don Kim, Young‐In Yoon, Dong‐Hwan Jung, Gil‐Chun Park, Chul‐Soo Ahn, Deok‐Bog Moon, Shin Hwang, Ki‐Hun Kim, Gi‐Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek‐Yeol Ryoo, Sung‐Gyu Lee
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2572-2579 (2023)
Abstract Introduction Lenvatinib is approved for the treatment of patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, clinical outcomes of lenvatinib therapy in patients with post‐liver transplantation (LT) HCC recurrence
Externí odkaz:
https://doaj.org/article/3a4d488f1ccf435b83b8ccfb949c2e89
Autor:
Hyung-Don Kim, Seyoung Jung, Ho Yeong Lim, Baek-Yeol Ryoo, Min-Hee Ryu, Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok-Bog Moon, Ki-Hoon Kim, Tae Won Kim, Jeong Seok Lee, Richard S. Finn, June-Young Koh, Changhoon Yoo
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709). Here we r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e24ad3eff16aefcb685092da825f8c7
Autor:
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa
Publikováno v:
Liver Cancer, Pp 1-10 (2021)
Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In
Externí odkaz:
https://doaj.org/article/a9aecdc91b464f2abd10eaa8419833fa
Autor:
Sora Kang, Jae Ho Jeong, Shinkyo Yoon, Changhoon Yoo, Kyu-pyo Kim, Hyungwoo Cho, Baek-Yeol Ryoo, Jinhong Jung, Jeong Eun Kim
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Cancer of unknown primary (CUP) is a heterogeneous malignancy in which the primary site of the tumor cannot be identified through standard work-up. The survival outcome of CUP is generally poor, and there is no consensus for treatment. Here,
Externí odkaz:
https://doaj.org/article/8d52adec9532400fb509dd2322c3ccfb